Bausch Health Companies (TSE:BHC) Stock Price Down 8.7% – Should You Sell?

Bausch Health Companies Inc. (TSE:BHC) shares fell 8.7% on Wednesday . The stock traded as low as C$10.67 and last traded at C$10.77. 62,824 shares were traded during trading, a decline of 83% from the average session volume of 365,759 shares. The stock had previously closed at C$11.80.

Analysts Set New Price Targets

Separately, Evercore ISI raised shares of Bausch Health Companies to a “hold” rating in a report on Tuesday, October 15th.

Bausch Health Companies Stock Up 2.6 %

The company has a debt-to-equity ratio of 7,583.76, a quick ratio of 0.58 and a current ratio of 1.19. The company has a market cap of C$4.04 billion, a P/E ratio of -6.29, a price-to-earnings-growth ratio of 0.21 and a beta of 0.77. The business’s fifty day moving average is C$11.70 and its two-hundred day moving average is C$9.89.

Bausch Health Companies (TSE:BHC) last announced its quarterly earnings results on Wednesday, October 30th. The company reported C$1.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of C$1.43 by C$0.10. Bausch Health Companies had a negative return on equity of 2,304.54% and a negative net margin of 5.12%. The firm had revenue of C$3.42 billion during the quarter, compared to analyst estimates of C$3.36 billion. Equities analysts predict that Bausch Health Companies Inc. will post 5.5472637 EPS for the current year.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.